Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Roshni Ramchandani"'
Autor:
Roshni Ramchandani, E Rock, C Dartois, Brian Booth, Yaning Wang, Cynthia Sung, Jogarao V. S. Gobburu
Publikováno v:
Clinical Pharmacology & Therapeutics. 86:167-174
Four non-small-cell lung cancer (NSCLC) registration trials were utilized to develop models linking survival to risk factors and changes in tumor size during treatment. The purpose was to leverage existing quantitative knowledge to facilitate future
Autor:
Jogarao V. S. Gobburu, Edwin P. Rock, Cheng Yi Liang, Sophia Abraham, Nallaperumal Chidambaram, S. Leigh Verbois, David E. Morse, Janet X. Jiang, Shenghui Tang, Richard Pazdur, Robert Justice, Roshni Ramchandani, Vicki L. Goodman, Ramzi Dagher, Brian Booth, Kooros Mahjoob
Publikováno v:
Clinical Cancer Research. 13:1367-1373
Purpose: To describe the Food and Drug Administration (FDA) review and approval of sunitinib malate (Sutent). Sunitinib received regular approval for the treatment of gastrointestinal stromal tumor (GIST) after disease progression or intolerance to i
Autor:
Nam Atiqur Rahman, Ramana S. Uppoor, B. Nhi Beasley, Raman K. Baweja, Patrick J. Marroum, Chandrahas G. Sahajwalla, Veneeta Tandon, Roshni Ramchandani, Brian Booth, Venkatesh A. Bhattaram, J. Robert Powell, John Duan, Jogarao V. S. Gobburu, Mehul Mehta, Yaning Wang
Publikováno v:
The AAPS Journal. 7:E503-E512
The value of quantitative thinking in drug development and regulatory review is increasingly being appreciated. Modeling and simulation of data pertaining to pharmacokinetic, pharmacodynamic, and disease progression is often referred to as the pharma
Autor:
Ramzi Dagher, Robert Justice, Christine Garnett, Xiaoping Jiang, Shwu-Luan Lee, Richard Pazdur, Maitreyee Hazarika, Qi Liu, John K. Leighton, Ravi Harapanhalli, William Timmer, Micheal S. Orr, Brian Booth, Roshni Ramchandani, Rajeshwari Sridhara
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(17)
Purpose: This Food and Drug Administration (FDA) approval report describes the data and analyses leading to the approval by the FDA of nilotinib (Tasigna, AMN-107; Novartis Pharmaceuticals Corporation), an inhibitor of Bcr-Abl tyrosine kinase, for th
Autor:
William Timmer, Xiaoping Jiang, Edvardas Kaminskas, Julie Bullock, Haleh Saber, Vicki L. Goodman, Rajeshwari Sridhara, Michael Brave, Leslie Kenna, David L. Morse, Richard Pazdur, Ravi Harapanhalli, Brian Booth, Joga Gobburu, Angela Men, Robert Justice, Roshni Ramchandani, Ann T. Farrell, Carol Noory, Sarah Pope
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(2)
Purpose: On June 28, 2006, the U.S. Food and Drug Administration approved dasatinib (Sprycel; Bristol-Myers Squibb), a new small-molecule inhibitor of multiple tyrosine kinases, for the treatment of adults with chronic phase, accelerated phase, or my
Publikováno v:
Europe PubMed Central
Immature rabbits have greater maximal airway narrowing and greater maximal fold increases in airway resistance during bronchoconstriction than mature animals. We have previously demonstrated that excised immature rabbit lungs have more distensible ai